🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

22 recruiting trials

for Plaque Psoriasis Patients

Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis NCT06842199Phase 346 sites📍 Hefei📍 Wuhu📍 Beijing Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-488 Tablets, ICP-488 Placebo A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis NCT07724366Phase 345 sites📍 Beijing📍 Chongqing📍 Chongqing Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: TQH3906 capsules, Deucravacitinib tablets 6 mg, TQH3906 Capsules placebo, Deucravacitinib tablets placebo A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD NCT07683065n/a7 sites📍 Badalona📍 Barcelona📍 Barcelona Novartis Pharmaceuticals Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23) NCT06792487n/a1 site📍 Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Tests: skin biopsy SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) NCT07021495n/a8 sites📍 Nijmegen📍 Maastricht📍 Amsterdam Leiden University Medical Center Serum Substance P, Neuropathic Pain, and Central Sensitization Across Treatment Groups in Chronic Plaque Psoriasis NCT07844772n/a1 site📍 Istanbul Istanbul Training and Research Hospital · Tests: IL-17 Inhibitor Therapy, Conventional Systemic Therapy A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania NCT07582783n/a20 sites📍 Bârlad📍 Brasov📍 Bucharest Janssen Research & Development, LLC To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Presented to Tertiary Care Hospital NCT07337434EARLY Phase 11 site📍 Peshawar Syeda Sana Zaman · Tests: Methotrexate, Apremilast ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar NCT06997055n/a1 site📍 Amiens Celltrion HealthCare France · Tests: Ustekinumab 45 mg, Ustekinumab 90 mg A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis NCT06030076n/a1 site📍 Graz Almirall, S.A. · Tests: Tildrakizumab Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis NCT07251998Phase 21 site📍 Shanghai Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-332 Tablets, ICP-332 Tablets, ICP-332 Tablets, ICP-332 Placebo Tablets Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques NCT05642182Phase 13 sites📍 Pompano Beach📍 Fargo📍 Philadelphia SFA Therapeutics · Tests: SFA002, SFA002 Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis NCT03827876Phase 41 site📍 East Windsor Psoriasis Treatment Center of Central New Jersey · Tests: Enstilar 0.005%-0.064% Topical Foam Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and Non-pustular Palmoplantar Psoriasis NCT07545902NA1 site📍 Chieti ICIM International S.r.l. · Tests: PROXERA PSOMED 20 cream; PROXERA PSOMED 40 gel A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis NCT07265284Phase 31 site📍 Beijing Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tests: IBI112, placebo A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis NCT07129382Phase 1, Phase 211 sites📍 Beijing📍 Beijing📍 Chengde Chipscreen Biosciences, Ltd. · Tests: CS32582 capsule（low dose） or matched placebo, CS32582 capsule（high dose） or matched placebo, CS32582 capsule（low dose）,… Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis NCT04537689Phase 41 site📍 Outram Park Singapore General Hospital · Tests: Ixekizumab, Methotrexate, Cyclosporin A, Acitretin Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea NCT06258668n/a2 sites📍 Seoul📍 Seoul Bristol-Myers Squibb · Tests: Deucravacitinib Modifying PEST for Psoriatic Arthritis Screening NCT06382051NA30 sites📍 Calgary📍 Edmonton📍 Edmonton Novartis Pharmaceuticals · Tests: PEST Screening group Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) NCT07611747Phase 417 sites📍 Alicante📍 Elche📍 Orihuela Instituto de Investigación Marqués de Valdecilla · Tests: Carotid Ultrasound, High-intensity lipid-lowering therapy, Standard care according to ESC 2021 guidelines Phase II Clinical Trial of SHR-1139 Injection in Patients With Psoriasis NCT07719530Phase 21 site📍 Guangzhou Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: The SHR-1139 injection, placebo Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis NCT07039110n/a84 sites📍 Calgary📍 Edmonton📍 Winnipeg AbbVie
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy